Vaxcyte, Inc. — Director's Dealing 2021

Nov 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-11-18

Reporting Person: GUGGENHIME ANDREW (President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-18	Common Stock	M	3100	$5.35	Acquired	6225	Direct
2021-11-18	Common Stock	S	2985	$24.50	Disposed	3240	Direct
2021-11-18	Common Stock	S	115	$25.20	Disposed	3125	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-18	Stock Option (right to buy)	$5.35	M	3100	Disposed	2030-05-11	Common Stock (3100)	Direct

Footnotes

F1: Includes shares acquired under the Vaxcyte, Inc. employee stock purchase plan on November 17, 2020 of 1,562 shares and May 17, 2021 of 1,563 shares.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.04 to $24.86. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.08 to $25.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.